干扰素与核苷(酸)类似物联合治疗开创HBsAg转阴之路  

Combination therapy with interferons and nucleos(t)ide analogues creating a new way of HBsAg clearance

作　　者：陈新月[1] 柳雅立[1] 

机构地区：[1]首都医科大学附属北京佑安医院国际医疗部,100069

出　　处：《传染病信息》2015年第5期262-265,共4页Infectious Disease Information

基　　金：国家"十二五"科技重大专项(2012ZX1000 2003;2013ZX10002002-006);北京市科委首都特色临床项目(Z15110000405181);重大传染病协同创新项目(PXM2015-014226-000058)

摘　　要：干扰素与核苷(酸)类似物是目前用于慢性乙型肝炎抗病毒治疗的两大类药物,各有其优缺点,但单药总体治疗效果有限。两类药物联合治疗在10年前并不被推荐,然而近年大型前瞻性、多中心研究及临床实践均证实联合治疗可降低耐药率,提高HBe Ag血清转换率,实现更多HBs Ag清除。本文拟对干扰素与核苷(酸)类似物联合或序贯治疗的一些新证据进行阐释,并就联合治疗的前景进行展望。Interferons and nucleos（t）ide analogues are currently 2 major classes of antiviral agents utilized in treatment of chronic hepatitis B. Each has its advantages and disadvantages, but the overall treatment efficacy of a monotherapy is limited. The combination therapy with interferons and nucleos（ t） ide analogues was not recommended 10 years ago, however, in recent years several large prospective and multinational clinical trials have confirmed that the combination therapy can reduce drug resistance, improve HBe Ag seroconversion, and achieve more HBs Ag clearance. The authors discuss the new evidences about combination or sequential therapy with interferons and nucleos（t）ide analogues in treatment of chronic hepatitis B, and look into the future of combination therapy.

关 键 词：肝炎 乙型 慢性 干扰素类 核苷酸类 

分 类 号：R512.62[医药卫生—内科学]